PE15882015A1 - Vaccine against dengue virus - Google Patents

Vaccine against dengue virus

Info

Publication number
PE15882015A1
PE15882015A1 PE2015001630A PE0016302015A PE15882015A1 PE 15882015 A1 PE15882015 A1 PE 15882015A1 PE 2015001630 A PE2015001630 A PE 2015001630A PE 0016302015 A PE0016302015 A PE 0016302015A PE 15882015 A1 PE15882015 A1 PE 15882015A1
Authority
PE
Peru
Prior art keywords
dengue virus
against dengue
vaccine against
adjuvant
virus
Prior art date
Application number
PE2015001630A
Other languages
Spanish (es)
Inventor
Benoit Baras
Dirk Gheysen
Isabelle Solange Lucie Knott
Jean-Paul Prieels
Jean-Francois Toussaint
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15306009P priority Critical
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE15882015A1 publication Critical patent/PE15882015A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/381Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus
    • Y02A50/384Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus
    • Y02A50/385Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus the disease being Dengue
    • Y02A50/386Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus the disease being Dengue the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera

Abstract

La presente descripcion se refiere a composiciones inmunogenicas que inducen una respuesta inmune contra el virus del dengue. The present disclosure relates to immunogenic compositions which induce an immune against dengue virus response. Mas especificamente, se refiere a vacunas del virus del dengue inactivado que incluyen un adyuvante. More specifically, it relates to vaccines virus inactivated dengue including an adjuvant. Las composiciones descritas en la presente memoria incluyen un adyuvante sin aluminio capaz de promover una respuesta inmune Th1. The compositions described herein include an adjuvant without aluminum capable of promoting a Th1 immune response. Tambien se describen metodos para su uso, por ejemplo, en la formulacion de medicamentos para la prevencion o el tratamiento de enfermedades producidas por el virus del dengue Also methods for their use are described, for example in the formulation of drugs for the prevention or treatment of diseases caused by dengue virus
PE2015001630A 2009-02-17 2010-02-16 Vaccine against dengue virus PE15882015A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15306009P true 2009-02-17 2009-02-17

Publications (1)

Publication Number Publication Date
PE15882015A1 true PE15882015A1 (en) 2015-11-18

Family

ID=42174405

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001630A PE15882015A1 (en) 2009-02-17 2010-02-16 Vaccine against dengue virus
PE2011001431A PE09922011A1 (en) 2009-02-17 2010-02-16 immunogenic composition comprising an antigen of the dengue virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001431A PE09922011A1 (en) 2009-02-17 2010-02-16 immunogenic composition comprising an antigen of the dengue virus

Country Status (22)

Country Link
US (2) US9265821B2 (en)
EP (1) EP2398821B1 (en)
JP (2) JP6058266B2 (en)
KR (1) KR101738704B1 (en)
CN (1) CN102395600B (en)
AR (1) AR075437A1 (en)
AU (1) AU2010215595A1 (en)
BR (1) BRPI1011224A2 (en)
CA (1) CA2752809A1 (en)
CL (1) CL2011001993A1 (en)
CO (1) CO6551750A2 (en)
DO (1) DOP2011000268A (en)
ES (1) ES2649020T3 (en)
IL (1) IL214385A (en)
MX (1) MX338898B (en)
NZ (1) NZ700477A (en)
PE (2) PE15882015A1 (en)
SG (2) SG2014014385A (en)
TW (2) TWI528972B (en)
UY (1) UY32457A (en)
WO (1) WO2010094663A1 (en)
ZA (1) ZA201105656B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5988492B2 (en) 2009-09-02 2016-09-07 ノバルティス アーゲー Immunogenic composition comprising a TLR activity modulator
NZ608362A (en) 2010-09-01 2015-11-27 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
CA2837145A1 (en) * 2011-05-26 2012-11-29 Glaxosmithkline Biologicals Sa Inactivated dengue virus vaccine
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
BE1024160B9 (en) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Immunogenic formulation
US20190201520A1 (en) * 2016-05-10 2019-07-04 Najít Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein Immunogenic membrane protein complex, seen for the front up and tell priority over derav as immune stimulant and as vaccine
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0689454T4 (en) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccine preparations containing 3-O-deacylated monophosphoryl lipid A
RU2154068C2 (en) 1993-11-17 2000-08-10 Лаборатуар Ом С.А. Glucosamine disaccharides, method of preparing thereof, and pharmaceutical composition
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU693022B2 (en) 1995-04-25 1998-06-18 Smithkline Beecham Biologicals (Sa) Vaccines containing a saponin and a sterol
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1999011241A1 (en) * 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999064301A1 (en) 1998-06-08 1999-12-16 Sca Emballage France Fast flattening packaging
EP1091928B1 (en) 1998-06-30 2007-02-28 OM Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
IL142395D0 (en) * 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2000057907A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
AU776638B2 (en) 1999-03-26 2004-09-16 Walter Reed Army Institute Of Research Adaptation of virus to vertebrate cells
JP2002542203A (en) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
DK1402075T3 (en) 2001-05-22 2013-02-11 Us Gov Nat Inst Health Development of suitable mutations for attenuation of dengue viruses as well as chimeric dengue viruses
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
CA2618306C (en) 2005-08-08 2014-10-21 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
JP4828189B2 (en) * 2005-09-14 2011-11-30 雅美 森山 Secretory IgA and IgG antibody inducer
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
PT2086582E (en) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vaccine comprising an oil in water emulsion adjuvant
FR2896162B1 (en) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion oil in thermoreversible water
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination

Also Published As

Publication number Publication date
US20110318407A1 (en) 2011-12-29
MX338898B (en) 2016-05-03
SG173194A1 (en) 2011-09-29
TW201043245A (en) 2010-12-16
TWI528972B (en) 2016-04-11
UY32457A (en) 2011-01-31
US20160120972A1 (en) 2016-05-05
TW201517915A (en) 2015-05-16
JP2015221803A (en) 2015-12-10
CO6551750A2 (en) 2012-10-31
DOP2011000268A (en) 2012-07-31
PE09922011A1 (en) 2012-02-12
JP2012517979A (en) 2012-08-09
WO2010094663A1 (en) 2010-08-26
CN102395600A (en) 2012-03-28
CN102395600B (en) 2015-03-25
KR20110132379A (en) 2011-12-07
KR101738704B1 (en) 2017-06-08
IL214385A (en) 2016-11-30
NZ700477A (en) 2016-04-29
CL2011001993A1 (en) 2012-04-09
IL214385D0 (en) 2011-09-27
ZA201105656B (en) 2012-04-25
SG2014014385A (en) 2014-04-28
EP2398821A1 (en) 2011-12-28
EP2398821B1 (en) 2017-08-30
ES2649020T3 (en) 2018-01-09
JP6104988B2 (en) 2017-03-29
AR075437A1 (en) 2011-03-30
MX2011008649A (en) 2011-09-06
AU2010215595A1 (en) 2011-08-25
US9265821B2 (en) 2016-02-23
CA2752809A1 (en) 2010-08-26
JP6058266B2 (en) 2017-01-11
BRPI1011224A2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
CR20170279A (en) Polycyclic compounds and their pharmaceutical use carbamoilpiridona
CL2012003226A1 (en) Compounds derived from 5-fluoro-1H-pyrazolopyridine; preparation process thereof; framaceutica composition that comprises; and their use in the treatment of cardiovascular, sexual and metabolic diseases.
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
CL2014002077A1 (en) pharmaceutical composition comprising dimethyl fumarate; Preparation method; microtablets capsule comprising dimethyl fumarate; method for the treatment, prevention or amelioration of multiple sclerosis.
CY1117874T1 (en) USE OF A VIRUS SUBTYPES AND A EMULSION adjuvant oil-in-water to proklisi RESPONSE cd4 of T-cells and / or improved responsiveness -cell MEMORY
CR11461A (en) Antibody formulation
SG188104A1 (en) Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants
DK2459216T3 (en) Immunogenic compositions including tlr activity modulators
CY1118347T1 (en) Synthetic glucopyranosyl lipid adjuvant and FORMATIONS vaccines that contain
CL2015000295A1 (en) Compounds derived alquilpirimidina; pharmaceutical composition which comprises; use for the treatment of viral infections and other diseases.
CO6251369A2 (en) Influenza vaccine emulsion oil in water
UY33797A (en) pharmaceutical compositions for the treatment of HCV
CL2012002489A1 (en) Compounds derived naphtho-imidazole silyl; pharmaceutical composition; and their use to prevent or treat an infection by Hepatitis C virus.
GT201500021A (en) Sulfamoilarilamidas and their use as medicaments for the treatment of hepatitis b
DOP2016000316A (en) Cyclic dinucleotides as modulators sting
EA201270063A1 (en) Pcb recombinant antigens
WO2009156960A9 (en) Novel adjuvant compositions
CL2015000870A1 (en) Analogs 2 '-chloro nucleoside for HCV infection.
CL2016002179A1 (en) Heteroarildihidropirimidinas new 6-fused for treatment and prophylaxis of infection by Hepatitis B Virus.
IN2012DN02736A (en) "compounds and compositions as tlr activity modulators"
CL2017001932A1 (en) Cyclic dinucleotides useful for the treatment of cancer among others.
CL2007001698A1 (en) immunogenic composition comprising meningococcal lipooligosaccharide (the) of immunotypes L2 and L3 of neissericas strains; vaccine composition that comprises; preparation process; and its use for the prevention or treatment of diseases caused by one or more serogroups n. meningitidis.
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AR053711A1 (en) Combination vaccines for porcine circovirus and helicobacter and methods of use
MX2010012999A (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof.

Legal Events

Date Code Title Description
FD Application declared void or lapsed